Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Z Gastroenterol ; 43(1): 11-6, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15650966

ABSTRACT

BACKGROUND: The diagnosis of chronic hepatitis C virus infection is based on nucleic acid testing (NAT) for HCV-RNA. We evaluated whether total HCV core antigen testing could be a substitute for NAT testing. PATIENTS AND METHODS: Samples from 192 untreated chronic HCV positive patients previously tested for HCV-RNA by four different commercially available assays (SuperQuant, Amplicor HCV Monitor v 1.0 and v 2.0, Quantiplex) were tested for total HCV core antigen using the Ortho trak-C assay (Ortho Clinical Diagnostics, Raritan, NJ, USA). Furthermore, 52 HCV-RNA positive paired serum and plasma samples were analysed. Finally, inter-assay coefficients of variation for core antigen were determined by repeated testing of 59 samples. RESULTS: 172/192 (89.6 %) samples from untreated HCV patients showed positive results with the trak-C assay. Importantly, all but two trak-C positive samples were NAT positive. Only four of the twenty trak-C negative samples tested positive by two NAT assays with viral loads below 30,000 copies/mL. Moreover, HCV core antigen levels correlated significantly with HCV-RNA levels (r > 0.72; p > 0.001), gave consistent results in paired serum and plasma samples (r = 0.991), and showed a very low inter-assay variability (r = 0.943) independent of genotype. CONCLUSION: Based on the performance characteristics, easiness of use, and potential lower cost of the core Ag assay, we propose an alternative testing algorithm for establishing the diagnosis of chronic HCV infection in which the trak-C assay could substitute for NAT as the first choice for detection of HCV viraemia in anti-HCV positive individuals. NAT would only be necessary in rare cases with low viral load.


Subject(s)
Algorithms , Diagnosis, Computer-Assisted/methods , Enzyme-Linked Immunosorbent Assay/methods , Hepatitis C/blood , Hepatitis C/diagnosis , Polymerase Chain Reaction/methods , Viral Core Proteins/blood , Biomarkers/blood , Hepatitis C/genetics , Hepatitis C/immunology , Humans , Reproducibility of Results , Sensitivity and Specificity , Statistics as Topic
2.
Histochem Cell Biol ; 113(2): 145-50, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10766267

ABSTRACT

The clonal rat calvaria cell line RCJ3.1C5.18 (RCJ) undergoes chondrogenic differentiation after long-term culture post confluence. To allow flexible genetic manipulation, a tetracycline-regulated gene expression system was established in this cell line. Treatment with tetracycline in operational doses does not affect the differentiation of RCJ cells with respect to the markers tested. After stable transfection with pUHD15.1 containing the tetracycline transactivator (tTA) in the presence of pTK-hyg for hygromycin selection, 28 clones were isolated and characterized for alcian blue staining of cartilage-specific proteoglycans and for collagen type II expression. Clone R-tTA-24 was selected on the basis of phenotype and displayed tetracycline-dependent down-regulation of luciferase activity (tet-OFF system) by two orders of magnitude (57-149-fold) after stable transfection with the reporter gene pBI-EGFP/luc. The novel, chondrogenic cell line R-tTA-24 may be stably transfected with various genes of interest for tetracycline-regulated gene expression using neomycin selection and may be a valuable tool to study the process of chondrogenic differentiation in vitro.


Subject(s)
Chondrogenesis , Gene Expression Regulation/drug effects , Skull/cytology , Tetracycline/pharmacology , Alcian Blue , Animals , Cell Differentiation , Cell Line , Clone Cells , Coloring Agents , Genes, Reporter , Genetic Engineering , Luciferases/genetics , Protein Engineering , Rats , Recombinant Fusion Proteins/biosynthesis , Repressor Proteins/genetics , Trans-Activators/genetics , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...